We have previously reported the effects of 2-(trimethylammonium)ethyl (R)-3-methoxy-3-oxo-2-stearamidopropyl phosphate [(R)-TEMOSPho], a synthetic phospholipid, on megakaryocytic differentiation of myeloid leukemia cells. Here, we demonstrate that (R)-TEMOSPho enhances megakaryopoiesis and plateletogenesis from primary hematopoietic stem cells (HSCs) induced by thrombopoietin (TPO). Specifically, we demonstrate at sub-saturation levels of TPO, the addition of (R)-TEMOSPho enhances differentiation and maturation of megakaryocytes (MKs) from murine HSCs derived from fetal liver. Furthermore, we show that production of platelets with (R)-TEMOSPho in combination with TPO is also more efficient than TPO alone and that platelets generated in vitro with these two agents are as functional as those from TPO alone. TPO can thus be partly replaced by or supplemented with (R)-TEMOSPho, and this in turn implies that (R)-TEMOSPho can be useful in efficient platelet production in vitro and potentially be a valuable option in designing cell-based therapy. [BMB Reports 2019; 52(7): 434-438]
INTRODUCTION
Platelets are anucleate cellular fragments found in large numbers in circulating blood (1) . They originate from MKs which have descended from HSCs and undergo endomitosis achieving polyploidy of upto 256N prior to apoptotic disintegration and release of platelets (2, 3) . Thrombosis and hemostasis are both mediated by platelets whose well balanced activity is thus crucial for vascular integrity and ultimately for survival. Platelets, currently obtained from donated blood, are used in various medical procedures including cancer treatments and certain types of surgery. Not surprisingly, not only is there a widespread shortage problem, but side effects such as febrile and anaphylactoid reactions and blood-borne infections remain as unresolved risk factors (4) .
Numerous efforts to generate platelets in vitro have been made, and most of recent attempts are based essentially on a sequential differentiation of embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs) first to HSCs and then to polyploidy MKs which can subsequently undergo apoptosis and release platelets (5) (6) (7) (8) . The key reagent for both the generation of HSCs and the induction of megakaryocytic differentiation is TPO. The need for this humoral growth factor and its receptor, CD110 encoded by c-mpl gene, in generation of platelets via maturation of MKs is well demonstrated both in vitro and in vivo (9, 10) . Indeed, virtually all procedures reporting in vitro platelet generation to date use TPO as the essential element (5) (6) (7) (8) .
Generation and purification of large quantities of TPO suitable for application in cell culture-based production is likely to be highly costly. Here, we describe an alternate strategy utilizing (R)-TEMOSPho, a synthetic chemical previously shown to induce megakaryocytic differentiation of myeloid leukemia cells, as a supplement to TPO (11, 12) . Specifically, we show that (R)-TEMOSPho, which cannot by itself induce efficient MK differentiation of murine HSCs, can enhance TPO activity in megakaryocytic differentiation and plateletogenesis. This implies that (R)-TEMOSPho can potentially be a useful reagent in efficient in vitro production of platelets and possibly in therapeutic settings.
RESULTS AND DISCUSSION
We have previously shown that (R)-TEMOSPho can efficiently induce megakaryocytic differentiation of K562 and HEL cells which are myeloid leukemia cells (12) . In order to examine its function in primary cells, we applied (R)-TEMOSPho to murine http://bmbreports.org BMB Reports embryonic HSCs prepared from E12.5 fetal liver. Although a slight increase in the proportion of CD41(+) cells was noted, the induction of megakaryocytic differentiation was overall negligible (Fig. 1A) . Furthermore, the inductive effect on CD41 expression was not enhanced at higher levels of (R)-TEMOSPho. In fact, beyond 50 g/ml of the reagent, we noted cell death, a http://bmbreports.org likely side effect of high dosage. This was in contrast to the effect of TPO which induced CD41 expression in a dose dependent manner maximally around 100 ng/ml (Fig. 1A) . We were curious to see if (R)-TEMOSPho could nevertheless contribute to megakaryocytic differentiation by enhancing the effect of TPO.
(R)-TEMOSPho and sub-maximal doses of TPO were applied in combination, and CD41 expression was examined. Interestingly, 25 g/ml of (R)-TEMOSPho in combination with 25 or 50 ng/ml of TPO could induce the proportions of CD41(+) cells to the near maximal level achieved by 100 ng/ml of TPO (Fig. 1B) . The bona fide induction of megakaryocytic differentiation was also confirmed by visible increase in cellular size (Fig. 1C) .
Another hallmark phenotype associated with megakaryopoiesis is endomitosis and resulting polyploidy. Indeed, TPO treatment readily induced increase in chromosomal content ( Fig. 2A) . As in the case of cellular enlargement, supplementing submaximal level of TPO (25 ng/ml) with (R)-TEMOSPho promoted polyploidization. Notably, cells with higher chromosomal contents of 16N and 32N were relatively enriched among cells treated with both TPO and (R)-TEMOSPho even when compared to cells treated with 100 ng/ml of TPO. The increase in chromosomal content was also confirmed via fluorescence microscopy with DAPI-staining for chromosomes and F-actin staining to delineate cellular boundaries (Fig. 2B) .
We next investigated whether culture-derived MKs can produce platelets and if (R)-TEMOSPho can aid TPO in the process. Proplatelet-like projections were readily seen in TPOtreated cultures, and supplementing with (R)-TEMOSPho appeared to enhance the level induced by the sub-maximal concentration of TPO (Fig. 3A) . In order to quantify the plateletogenesis, we followed a previously established protocol for isolating platelets from mouse sera based on forward and side scatter properties and assessing the platelet level based on CD41 expression (5, 12, 13) . Using mouse blood-derived platelet preparation as the positive control, we isolated platelet populations with identical flow cytometric characteristics. The proportions of CD41(+) cellular particles clearly indicated that supplementing with (R)-TEMOSPho significantly stimulated the plateletogenesis induced by TPO (Fig. 3B) . Next, we examined whether culture-derived platelets are functional. Mouse platelets described as above were used as the positive control. First, we investigated the expression of P-selectin, a cell adhesion molecule on the surface of activated platelets. Upon stimulation with the agonist peptide AYPGKF, platelets prepared from various conditions showed positive response to P-selectin by flow cytometric analyses consistent with activation of PAR4 receptor activation and translocation of P-selectin to the cell surface (Fig. 4A) . We also examined fibrinogen-binding activity. Again, upon activation with the peptide AYPGKF, a strong binding to fluoroprobe-coupled fibrinogen was seen for culture-derived platelets as well as for mouse blood-derived platelets (Fig. 4B) . Lastly, we visually examined the platelet aggregation upon activation. Indeed, phase-contrast microscopic examination showed clear aggregation post activation consistent with functionality of the platelets (Fig. 4C) .
In sum, we have demonstrated that (R)-TEMOSPho promotes TPO-induced megakaryocytic differentiation and platelet production from primary hematopoietic stem cells. This makes it possible to use sub-saturation levels of TPO in generating platelets in vitro and could potentially make the process more cost-efficient and thus viable as an alternative to platelet transfusion. Furthermore, our results also suggests that (R)-TEMOSPho is potentially applicable in TPO-based or c-mpl agonist-based therapeutic treatments as a supplement.
MATERIALS AND METHODS

Isolation and culture of HSCs
The plan for this study was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Ewha Womans University (No. 16-050). Timed pregnant mice were purchased from a commercial vendor (Orientbio Inc.). Mouse fetal livers were isolated from embryonic day (E) 12. (14) . Details are available upon request.
Flow cytometry
Cells were incubated with FITC conjugated anti-CD41 antibody (BD biosciences) and analyzed by flow cytometry using a FACS Calibur (BD biosciences) and the BD Cell-Quest TM Pro version 6.0 software (BD bioscience). For DNA content analysis, cells were incubate for 30 min at room temperature (RT) in staining solution (50 g/ml Propidium Iodide, 100 g/ml RNase A, 0.1% Triton X-100) and analyzed by FACS Calibur.
Phalloidin staining
Staining for F-actin with phalloidin to delineate cellular boundaries and counterstaining with 4'-6-Diamidino-2-phenylindole (DAPI) were carried out as previously described (11) .
Platelet functional assays
Platelet-rich plasma was prepared from mouse blood and resuspended in Tyrode buffer following a published protocol with minor modifications (5, 13) . Details are available upon request. For preparation of culture-derived mouse platelets, culture medium was collected and centrifuged at 150 g for 20 min to isolate the supernatant to which 1 M PGE1 and 0.1 U/ml apyrase in 9X volume of ACD solution (Sigma-Aldrich) were added. After centrifugation at 900 g for 10 min, the pellet was resuspended and washed with the washing solution containing 1 M PGE1 and 0.1 U/ml apyrase. The pellet containing platelets were finally isolated by centrifugation and resuspended in Tyrode buffer. To examine P-selectin expression, platelets were stimulated with 500 M AYPGKF (Peptron) and incubated for 15 min at 37 o C prior to incubation with FITC conjugated anti-CD62p antibody (BD Bioscience) for 15 min at RT and analysis by FACS. For the fibrinogen binding assay, platelets were first activated with 500 M AYPGKF and subsequently incubated with the 3ul Alexa 488-labelled fibrinogen (Invitrogen) for 30 min in the dark. The mixture was then diluted with 1X PBS and analyzed by FACS. For the aggregation assay, platelets were activated with 100 g/ml fibrinogen (Merck Millipore), 1 mM CaCl2, 1 mM MgCl2 and 500 M AYPGKF and incubated for at RT for 10 min. The activated platelets were applied to 2.5 mg/ml fibrinogen coated slide and examined for platelet aggregation under a phase-contrast microscope.
